Roche hits back at Novartis with new data for MS drug OcrevusRoche has hit back at Novartis’ newly-approved multiple sclerosis drug Kesimpta, with new data from its already-marketed blockbuster Share XRoche hits back at Novartis with new data for MS drug Ocrevushttps://pharmaphorum.com/news/roche-hits-back-at-novartis-with-new-data-for-ms-drug-ocrevus/
US, EU reviews start for Novartis’ Ocrevus rival ofatumumabNovartis’ cancer therapy ofatumumab has moved closer to its second life as a treatment for multiple sclerosis, with Share XUS, EU reviews start for Novartis’ Ocrevus rival ofatumumabhttps://pharmaphorum.com/news/us-eu-reviews-start-for-novartis-ocrevus-rival-ofatumumab/
Roche raises 2019 outlook, shrugging off biosimilar threatNew product sales helped Roche to a healthy 9% increase in sales in the first half of the Share XRoche raises 2019 outlook, shrugging off biosimilar threathttps://pharmaphorum.com/news/roche-raises-2019-outlook-shrugging-off-biosimilar-threat/
Addressing MS’ two-tier healthcare system is about ‘social justice’NICE has reversed its decision not to approve a new drug that offers hope to thousands of people Share XAddressing MS’ two-tier healthcare system is about ‘social justice’https://pharmaphorum.com/views-analysis-patients/ms-two-tier-healthcare-system/
Roche’s MS drug Ocrevus earns blockbuster status a year after launchRoche’s multiple sclerosis (MS) drug Ocrevus (ocrelizumab) has claimed blockbuster status just one year after it was launched. Share XRoche’s MS drug Ocrevus earns blockbuster status a year after launchhttps://pharmaphorum.com/news/roche-ms-ocrevus-blockbuster/
Roche’s MS drug Ocrevus nears European marketRoche’s new multiple sclerosis drug Ocrevus (ocrelizumab) gained FDA approval in March, and since then has achieved remarkable Share XRoche’s MS drug Ocrevus nears European markethttps://pharmaphorum.com/news/roches-multiple-sclerosis-drug-ocrevus-heading-european-market-received-backing-regulators/
Brain infection would be bad news for Roche’s MS drug OcrevusSuggestion is that PML case was caused by previous treatment. Share XBrain infection would be bad news for Roche’s MS drug Ocrevushttps://pharmaphorum.com/news/roche-investigates-ocrevus/